Гиппократ не рад. Путеводитель в мире медицинских исследований

75. Perkins, G. D. et al. A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest. N. Engl. J. Med. 379, 711–721 (2018).

76. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 6, e1000097 (2009).

77. Moher, D., Tetzlaff, J., Tricco, A. C., Sampson, M. & Altman, D. G. Epidemiology and Reporting Characteristics of Systematic Reviews. PLoS Med. 4, e78 (2007).

78. Shojania, K. G. et al. How Quickly Do Systematic Reviews Go Out of Date? A Survival Analysis. Ann. Intern. Med. 147, 224 (2007).

79. Health On the Net (HON): HONcode: Principles in Russian. Available at: http://www.hon.ch/HONcode/Webmasters/Russian/. (Accessed: 29th October 2018)

80. Грипп. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/influenza-(seasonal). (Accessed: 25th October 2018)

81. Influenza (Flu) Antiviral Drugs and Related Information | FDA. Available at: https://www.fda.gov/drugs/information-drug-class/influenza-flu-antiviral-drugs-and-related-information. (Accessed: 29th October 2018)

82. Influenza Antiviral Medications: Summary for Clinicians. Centers for Disease Control and Prevention Available at: https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm. (Accessed: 29th October 2018)

83. What You Should Know About Flu Antiviral Drugs | CDC. Available at: https://www.cdc.gov/flu/treatment/whatyoushould.htm. (Accessed: 29th October 2018)

84. Эффективность и безопасность гепатопротекторов с точки зрения доказательной медицины. Available at: http://health-ua.com/article/15676-effektivnost-i-bezopasnost-gepatoprotektorov-s-tochki-zreniya-dokazatelnoj-. (Accessed: 29th October 2018)

85. Saito, Z. et al. Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis. BMC Infect. Dis. 16, 668 (2016).

86. Rambaldi, A., Jacobs, B. P. & Gluud, C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst. Rev. (2007). doi:10.1002/14651858.CD003620.pub3

87. Day, P. et al. Клинические рекомендации EASL – EASD – EASO по диагностике и лечению неалкогольной жировой болезни печени (2016).

88. Ivashkin, V. et al. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. Vshtspb.Ru 24–42 (2013).

89. Elia, V. et al. Permanent physico-chemical properties of extremely diluted aqueous solutions of homeopathic medicines. Homeopathy 93, 144–50 (2004).

90. Kayne, S. B. Homeopathic pharmacy : theory and practice. (Elsevier Churchill Livingstone, 2006).

91. Chakraborti, D. et al. Arsenic toxicity from homeopathic treatment. J. Toxicol. Clin. Toxicol. 41, 963–7 (2003).

92. HRI – Homeopathy use around the world. Available at: https://www.hri-research.org/resources/essentialevidence/use-of-homeopathy-across-the-world/. (Accessed: 29th October 2018)

93. Dantas, F. et al. A systematic review of the quality of homeopathic pathogenetic trials published from 1945 to 1995. Homeopathy 96, 4–16 (2007).

94. Junod, S. W. An alternative perspective: homeopathic drugs, Royal Copeland, and federal drug regulation. Food Drug Law J. 55, 161–83 (2000).

95. Воробьев П. А., Безмельницына Л. Ю., Краснова Л. С. & Холовня М. А. Оценка медицинской технологии применения лекарственных препаратов с ноотропным и психостимулирующим действием: кортексин, пирацетам, цитиколин, церебролизин. Клиническая геронтология 53–73 (2017).

96. Flicker, L. & Grimley Evans, J. Piracetam for dementia or cognitive impairment. Cochrane Database Syst. Rev. (2004). doi:10.1002/14651858.CD001011

97. Cerebrolysin | EVER Pharma. Available at: https://www.everpharma.com/portfolio/neurology/cerebrolysin/. (Accessed: 29th October 2018)

98. Vastag, B. Biotechnology: Crossing the barrier. Nature 466, 916–918 (2010).

99. Chen, N. et al. Cerebrolysin for vascular dementia. Cochrane Database Syst. Rev. (2013). doi:10.1002/14651858.CD008900.pub2

100. Ziganshina, L. E., Abakumova, T. & Vernay, L. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst. Rev. (2017). doi:10.1002/14651858.CD007026.pub5

101. Смирнова М. Д. & Агеев Ф. Т. Статины – старые мифы и новые факты. Регулярные выпуски ‘РМЖ’ 1421–1428 (2017).

102. Chasman, D. I. et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291, 2821–7 (2004).

103. Liao, J. K. Safety and efficacy of statins in Asians. Am. J. Cardiol. 99, 410–4 (2007).